The Scottish Medicines Consortium (SMC) has completed its assessment of Avacopan and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees (ADTCs) on its use in NHSScotland.
Full details posted here: scottishmedicines.org.uk/me...
Indication under review: In combination with a rituximab or cyclophosphamide regimen, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
In a phase III study, avacopan demonstrated non-inferiority to prednisone for remission at week 26, and was superior to prednisone for sustained remission at week 52 in patients with GPA or MPA.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.